Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

  • Technology appraisal guidance
  • TA352
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research:

  • Rafia R, Scope A, Harnan S et al. Vedolizumab for the treatment of adults with moderately to severely active Crohn's disease: A Single Technology Appraisal, October 2014

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Takeda UK (vedolizumab)

II. Professional/expert and patient/carer groups:

  • British Society of Gastroenterology

  • Crohn's and Colitis UK

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association (UKCPA)

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • AbbVie (adalimumab)

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Merck Sharp & Dohme (infliximab)

  • Napp Pharmaceuticals (prednisolone)

  • National Institute for Health Research Health Technology Assessment Programme

  • School of Health and Related Research Sheffield (ScHARR)

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on vedolizumab by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Dr Seamus Murphy, Consultant Gastroenterologist, nominated by organisation and representing British Society of Gastroenterology – clinical expert

  • Dr Jeremy Sanderson, Consultant Gastroenterologist, nominated by organisation and representing British Society of Gastroenterology – clinical expert

  • Paula Battersby nominated by organisation and representing Crohn's and Colitis UK – patient expert

  • Andy Phillips nominated by organisation and representing Crohn's and Colitis UK – patient expert.

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Takeda UK